Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
47
SPHDF Quote, Financials, Valuation and Earnings
Last price:
$16.28
Seasonality move
:
11.09%
Day range:
$16.28 - $16.28
52-week range:
$9.42 - $19.00
Dividend yield:
0%
P/E ratio:
1.45x
P/S ratio:
3.68x
P/B ratio:
7.72x
Volume:
--
Avg. volume:
73
1-year change:
72.82%
Market cap:
$211.2M
Revenue:
$44.4M
EPS (TTM):
-$4.43
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
-- | -- | -- | -- | -- |
|
ACIU
AC Immune SA
|
$1.5M | -$0.22 | 11.32% | -18.31% | $9.21 |
|
BPMUF
Basilea Pharmaceutica AG
|
$93.1M | -- | -- | -- | -- |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -- | -- | -- |
|
ELVAF
EvoNext Holdings SA
|
-- | -- | -- | -- | -- |
|
ONC
BeOne Medicines Ltd.
|
$1.4B | $1.30 | 25.24% | 6838.6% | $406.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
$16.28 | -- | $211.2M | 1.45x | $0.00 | 0% | 3.68x |
|
ACIU
AC Immune SA
|
$2.93 | $9.21 | $294.8M | -- | $0.00 | 0% | 57.14x |
|
BPMUF
Basilea Pharmaceutica AG
|
$71.00 | -- | $871.3M | 10.28x | $0.00 | 0% | 3.61x |
|
CSBTF
Kuros Biosciences Ltd.
|
$32.00 | -- | $1.3B | -- | $0.00 | 0% | 9.78x |
|
ELVAF
EvoNext Holdings SA
|
$1.1000 | -- | $7.9M | 5.90x | $0.00 | 0% | 0.61x |
|
ONC
BeOne Medicines Ltd.
|
$351.27 | $406.00 | $38.9B | 675.78x | $0.00 | 0% | 7.85x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
33% | -6.454 | -- | 0.51x |
|
ACIU
AC Immune SA
|
6.95% | 3.733 | 2.01% | 1.10x |
|
BPMUF
Basilea Pharmaceutica AG
|
85.07% | 0.813 | -- | 2.96x |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -0.224 | -- | 1.61x |
|
ELVAF
EvoNext Holdings SA
|
-- | 0.210 | -- | -- |
|
ONC
BeOne Medicines Ltd.
|
31.57% | -0.304 | 5.05% | 2.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SPHDF
Santhera Pharmaceuticals Holding AG
|
-- | -- | 123.12% | 276.68% | -- | -- |
|
ACIU
AC Immune SA
|
-- | -$19.6M | -72.31% | -75.88% | -1671.93% | -$24.4M |
|
BPMUF
Basilea Pharmaceutica AG
|
-- | -- | -0.84% | -15.42% | -- | -- |
|
CSBTF
Kuros Biosciences Ltd.
|
-- | -- | -6.35% | -6.35% | -- | -- |
|
ELVAF
EvoNext Holdings SA
|
-- | -- | -- | -- | -- | -- |
|
ONC
BeOne Medicines Ltd.
|
$1.2B | $163.3M | 1.43% | 1.92% | 11.55% | $355.1M |
Santhera Pharmaceuticals Holding AG vs. Competitors
-
Which has Higher Returns SPHDF or ACIU?
AC Immune SA has a net margin of -- compared to Santhera Pharmaceuticals Holding AG's net margin of -1688.87%. Santhera Pharmaceuticals Holding AG's return on equity of 276.68% beat AC Immune SA's return on equity of -75.88%.
Company Gross Margin Earnings Per Share Invested Capital SPHDFSanthera Pharmaceuticals Holding AG-- -- $79.8M ACIUAC Immune SA-- -$0.20 $84.3M -
What do Analysts Say About SPHDF or ACIU?
Santhera Pharmaceuticals Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand AC Immune SA has an analysts' consensus of $9.21 which suggests that it could grow by 214.57%. Given that AC Immune SA has higher upside potential than Santhera Pharmaceuticals Holding AG, analysts believe AC Immune SA is more attractive than Santhera Pharmaceuticals Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings SPHDFSanthera Pharmaceuticals Holding AG0 0 0 ACIUAC Immune SA4 0 0 -
Is SPHDF or ACIU More Risky?
Santhera Pharmaceuticals Holding AG has a beta of -0.796, which suggesting that the stock is 179.584% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.660, suggesting its more volatile than the S&P 500 by 66.038%.
-
Which is a Better Dividend Stock SPHDF or ACIU?
Santhera Pharmaceuticals Holding AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Santhera Pharmaceuticals Holding AG pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPHDF or ACIU?
Santhera Pharmaceuticals Holding AG quarterly revenues are --, which are smaller than AC Immune SA quarterly revenues of $1.2M. Santhera Pharmaceuticals Holding AG's net income of -- is lower than AC Immune SA's net income of -$19.8M. Notably, Santhera Pharmaceuticals Holding AG's price-to-earnings ratio is 1.45x while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Santhera Pharmaceuticals Holding AG is 3.68x versus 57.14x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPHDFSanthera Pharmaceuticals Holding AG3.68x 1.45x -- -- ACIUAC Immune SA57.14x -- $1.2M -$19.8M
-
Which has Higher Returns SPHDF or BPMUF?
Basilea Pharmaceutica AG has a net margin of -- compared to Santhera Pharmaceuticals Holding AG's net margin of --. Santhera Pharmaceuticals Holding AG's return on equity of 276.68% beat Basilea Pharmaceutica AG's return on equity of -15.42%.
Company Gross Margin Earnings Per Share Invested Capital SPHDFSanthera Pharmaceuticals Holding AG-- -- $79.8M BPMUFBasilea Pharmaceutica AG-- -- $125.1M -
What do Analysts Say About SPHDF or BPMUF?
Santhera Pharmaceuticals Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Basilea Pharmaceutica AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Santhera Pharmaceuticals Holding AG has higher upside potential than Basilea Pharmaceutica AG, analysts believe Santhera Pharmaceuticals Holding AG is more attractive than Basilea Pharmaceutica AG.
Company Buy Ratings Hold Ratings Sell Ratings SPHDFSanthera Pharmaceuticals Holding AG0 0 0 BPMUFBasilea Pharmaceutica AG0 0 0 -
Is SPHDF or BPMUF More Risky?
Santhera Pharmaceuticals Holding AG has a beta of -0.796, which suggesting that the stock is 179.584% less volatile than S&P 500. In comparison Basilea Pharmaceutica AG has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.835%.
-
Which is a Better Dividend Stock SPHDF or BPMUF?
Santhera Pharmaceuticals Holding AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Basilea Pharmaceutica AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Santhera Pharmaceuticals Holding AG pays -- of its earnings as a dividend. Basilea Pharmaceutica AG pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPHDF or BPMUF?
Santhera Pharmaceuticals Holding AG quarterly revenues are --, which are smaller than Basilea Pharmaceutica AG quarterly revenues of --. Santhera Pharmaceuticals Holding AG's net income of -- is lower than Basilea Pharmaceutica AG's net income of --. Notably, Santhera Pharmaceuticals Holding AG's price-to-earnings ratio is 1.45x while Basilea Pharmaceutica AG's PE ratio is 10.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Santhera Pharmaceuticals Holding AG is 3.68x versus 3.61x for Basilea Pharmaceutica AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPHDFSanthera Pharmaceuticals Holding AG3.68x 1.45x -- -- BPMUFBasilea Pharmaceutica AG3.61x 10.28x -- --
-
Which has Higher Returns SPHDF or CSBTF?
Kuros Biosciences Ltd. has a net margin of -- compared to Santhera Pharmaceuticals Holding AG's net margin of --. Santhera Pharmaceuticals Holding AG's return on equity of 276.68% beat Kuros Biosciences Ltd.'s return on equity of -6.35%.
Company Gross Margin Earnings Per Share Invested Capital SPHDFSanthera Pharmaceuticals Holding AG-- -- $79.8M CSBTFKuros Biosciences Ltd.-- -- $65M -
What do Analysts Say About SPHDF or CSBTF?
Santhera Pharmaceuticals Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Kuros Biosciences Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Santhera Pharmaceuticals Holding AG has higher upside potential than Kuros Biosciences Ltd., analysts believe Santhera Pharmaceuticals Holding AG is more attractive than Kuros Biosciences Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SPHDFSanthera Pharmaceuticals Holding AG0 0 0 CSBTFKuros Biosciences Ltd.0 0 0 -
Is SPHDF or CSBTF More Risky?
Santhera Pharmaceuticals Holding AG has a beta of -0.796, which suggesting that the stock is 179.584% less volatile than S&P 500. In comparison Kuros Biosciences Ltd. has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.678%.
-
Which is a Better Dividend Stock SPHDF or CSBTF?
Santhera Pharmaceuticals Holding AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kuros Biosciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Santhera Pharmaceuticals Holding AG pays -- of its earnings as a dividend. Kuros Biosciences Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPHDF or CSBTF?
Santhera Pharmaceuticals Holding AG quarterly revenues are --, which are smaller than Kuros Biosciences Ltd. quarterly revenues of --. Santhera Pharmaceuticals Holding AG's net income of -- is lower than Kuros Biosciences Ltd.'s net income of --. Notably, Santhera Pharmaceuticals Holding AG's price-to-earnings ratio is 1.45x while Kuros Biosciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Santhera Pharmaceuticals Holding AG is 3.68x versus 9.78x for Kuros Biosciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPHDFSanthera Pharmaceuticals Holding AG3.68x 1.45x -- -- CSBTFKuros Biosciences Ltd.9.78x -- -- --
-
Which has Higher Returns SPHDF or ELVAF?
EvoNext Holdings SA has a net margin of -- compared to Santhera Pharmaceuticals Holding AG's net margin of --. Santhera Pharmaceuticals Holding AG's return on equity of 276.68% beat EvoNext Holdings SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SPHDFSanthera Pharmaceuticals Holding AG-- -- $79.8M ELVAFEvoNext Holdings SA-- -- -- -
What do Analysts Say About SPHDF or ELVAF?
Santhera Pharmaceuticals Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand EvoNext Holdings SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Santhera Pharmaceuticals Holding AG has higher upside potential than EvoNext Holdings SA, analysts believe Santhera Pharmaceuticals Holding AG is more attractive than EvoNext Holdings SA.
Company Buy Ratings Hold Ratings Sell Ratings SPHDFSanthera Pharmaceuticals Holding AG0 0 0 ELVAFEvoNext Holdings SA0 0 0 -
Is SPHDF or ELVAF More Risky?
Santhera Pharmaceuticals Holding AG has a beta of -0.796, which suggesting that the stock is 179.584% less volatile than S&P 500. In comparison EvoNext Holdings SA has a beta of -42.013, suggesting its less volatile than the S&P 500 by 4301.301%.
-
Which is a Better Dividend Stock SPHDF or ELVAF?
Santhera Pharmaceuticals Holding AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EvoNext Holdings SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Santhera Pharmaceuticals Holding AG pays -- of its earnings as a dividend. EvoNext Holdings SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPHDF or ELVAF?
Santhera Pharmaceuticals Holding AG quarterly revenues are --, which are smaller than EvoNext Holdings SA quarterly revenues of --. Santhera Pharmaceuticals Holding AG's net income of -- is lower than EvoNext Holdings SA's net income of --. Notably, Santhera Pharmaceuticals Holding AG's price-to-earnings ratio is 1.45x while EvoNext Holdings SA's PE ratio is 5.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Santhera Pharmaceuticals Holding AG is 3.68x versus 0.61x for EvoNext Holdings SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPHDFSanthera Pharmaceuticals Holding AG3.68x 1.45x -- -- ELVAFEvoNext Holdings SA0.61x 5.90x -- --
-
Which has Higher Returns SPHDF or ONC?
BeOne Medicines Ltd. has a net margin of -- compared to Santhera Pharmaceuticals Holding AG's net margin of 8.84%. Santhera Pharmaceuticals Holding AG's return on equity of 276.68% beat BeOne Medicines Ltd.'s return on equity of 1.92%.
Company Gross Margin Earnings Per Share Invested Capital SPHDFSanthera Pharmaceuticals Holding AG-- -- $79.8M ONCBeOne Medicines Ltd.83.86% $1.09 $6B -
What do Analysts Say About SPHDF or ONC?
Santhera Pharmaceuticals Holding AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $406.00 which suggests that it could grow by 15.58%. Given that BeOne Medicines Ltd. has higher upside potential than Santhera Pharmaceuticals Holding AG, analysts believe BeOne Medicines Ltd. is more attractive than Santhera Pharmaceuticals Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings SPHDFSanthera Pharmaceuticals Holding AG0 0 0 ONCBeOne Medicines Ltd.19 0 1 -
Is SPHDF or ONC More Risky?
Santhera Pharmaceuticals Holding AG has a beta of -0.796, which suggesting that the stock is 179.584% less volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.518, suggesting its less volatile than the S&P 500 by 48.23%.
-
Which is a Better Dividend Stock SPHDF or ONC?
Santhera Pharmaceuticals Holding AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Santhera Pharmaceuticals Holding AG pays -- of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPHDF or ONC?
Santhera Pharmaceuticals Holding AG quarterly revenues are --, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. Santhera Pharmaceuticals Holding AG's net income of -- is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, Santhera Pharmaceuticals Holding AG's price-to-earnings ratio is 1.45x while BeOne Medicines Ltd.'s PE ratio is 675.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Santhera Pharmaceuticals Holding AG is 3.68x versus 7.85x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPHDFSanthera Pharmaceuticals Holding AG3.68x 1.45x -- -- ONCBeOne Medicines Ltd.7.85x 675.78x $1.4B $125M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
66
DIOD alert for Feb 13
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
